&lt;p&gt;LncRNA ASB16-AS1 Promotes Growth And Invasion Of Hepatocellular Carcinoma Through Regulating miR-1827/FZD4 Axis And Activating Wnt/β-Catenin Pathway&lt;/p&gt;

Yao, Xiaoxiao; You, Guangqiang; Zhou, Chen; Zhang, Dan

doi:10.2147/cmar.s220434

Cited by 24 publications

(29 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, upregulation of ASB16-AS1 predicted low disease-free survival rate for patients with hepatocellular carcinoma. 27 Functionally, ASB16-AS1 exerted pro-oncogenic roles in glioma 26 and hepatocellular carcinoma. 27 Nevertheless, its expression and functions in OS have not been thoroughly investigated.…”

Section: Discussionmentioning

confidence: 99%

“…27 Functionally, ASB16-AS1 exerted pro-oncogenic roles in glioma 26 and hepatocellular carcinoma. 27 Nevertheless, its expression and functions in OS have not been thoroughly investigated. Data from the current study revealed that ASB16-AS1 expression was increased in OS tissues and cell lines.…”

Section: Discussionmentioning

confidence: 99%

“…ASB16 antisense RNA 1 (ASB16-AS1) is a cancerassociated lncRNA that contributes to tumorigenesis and tumor development. 26,27 However, to the best of our knowledge, whether and how ASB16-AS1 is implicated in OS malignancy remains unclear and therefore warrants exploration. Therefore, the present study aimed to investigate the detailed functions of ASB16-AS1 in OS.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

<p>Long Non-Coding RNA ASB16-AS1 Functions as a miR-760 Sponge to Facilitate the Malignant Phenotype of Osteosarcoma by Increasing HDGF Expression</p>

Yin

Liu

Zhao

et al. 2020

OTT

View full text Add to dashboard Cite

Purpose: ASB16 antisense RNA 1 (ASB16-AS1) is a cancer-associated long non-coding RNA that contributes to tumorigenesis and tumor development. Nevertheless, to the best of our knowledge, whether and how ASB16-AS1 is implicated in osteosarcoma (OS) malignancy remains unclear and therefore warrants exploration. Our current study focused on making in-depth investigation of ASB16-AS1 in OS. In the present study, the expression pattern of ASB16-AS1 in OS tissues and cell lines was analyzed. In addition, we examined the clinical value of ASB16-AS1 for OS patients. Furthermore, we explored the impacts of ASB16-AS1 on the malignant phenotype of OS cells in vitro and in vivo as well as the underlying mechanism. Methods: ASB16-AS1, microRNA-760 (miR-760) and hepatoma-derived growth factor (HDGF) expressions were measured using reverse transcription-quantitative PCR. Cell proliferation and apoptosis were evaluated using CCK-8 and flow cytometry analyses, respectively, and cell migration and invasion were determined via cell migration and invasion assays. Results: ASB16-AS1 expression was significantly elevated in OS tissues and cell lines, and increased ASB16-AS1 expression was related to patients' tumor size, TNM stage, and distant metastasis. The overall survival rate of OS patients presenting high ASB16-AS1 expression was shorter than that of patients presenting low ASB16-AS1 expression. Reduced ASB16-AS1 expression inhibited OS cell proliferation, migration, and invasion; promoted cell apoptosis; and impaired tumor growth in vivo. Mechanistically, ASB16-AS1 served as a sponge for miR-760 and positively modulated the expression of its target HDGF. Finally, inhibiting miR-760 and restoring HDGF expression abolished the impacts of ASB16-AS1 knockdown on the malignant characteristics of OS cells. Conclusion: ASB16-AS1 is a novel oncogenic lncRNA in OS cells. ASB16-AS1 increased HDGF expression by sponging miR-760, thereby conferring cancer-promoting roles in OS. ASB16-AS1 is a potential early diagnostic and therapeutic target in OS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Long Non-Coding RNA ASB16-AS1 Functions as a miR-760 Sponge to Facilitate the Malignant Phenotype of Osteosarcoma by Increasing HDGF Expression</p>

Yin

Liu

Zhao

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…Extensive evidence to date has indicated that lncRNAs can mediate the Wnt/β-catenin pathway by acting as ceRNAs of miRNAs, thereby modulating HCC cell proliferation and invasion; oncogenic lncRNAs that act as ceRNAs can perform their biological actions by activating the Wnt/β-catenin pathway in HCC. For example, frizzled (FZD) 4, a Wnt receptor, can activate the Wnt/β-catenin pathway in HCC[ 96 ], and the lncRNA ASB16-AS1 enhances FZD4 expression to activate the Wnt/β-catenin pathway by acting as a miR-1827 sponge and subsequently facilitates HCC growth and invasion[ 97 ]. Likewise, another Wnt receptor, FZD7, can also activate the Wnt/β-catenin pathway in HCC[ 98 ].…”

Section: Role Of Lncrnas As Cernas In Hccmentioning

confidence: 99%

Role of long noncoding RNA-mediated competing endogenous RNA regulatory network in hepatocellular carcinoma

Niu¹,

Wang²,

Dong³

et al. 2020

WJG

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) are noncoding RNAs (ncRNAs) that occupy over 90% of the human genome, and their main function is to directly or indirectly regulate messenger RNA (mRNA) expression and participate in the tumorigenesis and progression of malignances. In particular, some lncRNAs can interact with miRNAs as competing endogenous RNAs (ceRNAs) to modulate mRNA expression. Accordingly, these RNA molecules are interrelated and coordinate to form a dynamic lncRNA-mediated ceRNA regulatory network. Mounting evidence has revealed that lncRNAs that act as ceRNAs are closely related to tumorigenesis. To date, numerous studies have established many different regulatory networks in hepatocellular carcinoma (HCC), and perturbations in these ceRNA interactions may result in the initiation and progression of HCC. Herein, we emphasize recent advances concerning the biological function of lncRNAs as ceRNAs in HCC, with the aim of elucidating the molecular mechanism underlying these HCC-related RNA molecules and providing novel insights into the diagnosis and treatment of HCC.

show abstract

“…Studies found that E3 ligase β-TrCP1 (BTRC) target HuR for ubiquitin-mediated protein degradation 14,16 . Several studies have found that ASB16-AS1 regulate proliferation in glioma, hepatocellular carcinoma, cervical cancer, non-small cell lung cancer, and in osteosarcoma [17][18][19][20][21] . However, whether ASB16-AS1 plays an important role in adrenocortical carcinoma remains to be clarified.…”

Section: Introductionmentioning

confidence: 99%

Long noncoding RNA ASB16-AS1 inhibits adrenocortical carcinoma cell growth by promoting ubiquitination of RNA-binding protein HuR

Long

Yang

et al. 2020

Cell Death Dis

View full text Add to dashboard Cite

Adrenocortical carcinoma is one of the aggressive malignancies and it originates from the cortex of adrenal gland. Dysregulation of long non-coding RNA plays important roles in the development of adrenocortical carcinoma. Here, we found that lncRNA ASB16-AS1 was down-regulated in adrenocortical carcinoma and ASB16-AS1 functions as tumor suppressor in vitro and in vivo. We then found that IGF1R and CDK6 are regulated by ASB16-AS1 in adrenocortical carcinoma cells by transcriptome RNA sequencing. ASB16-AS1 associates with RNA-binding protein HuR (ELAVL1) as revealed by RNA pull-down following mass spectrometry. Also, ASB16-AS1 inhibits HuR expression post-translationally by promoting its ubiquitination. ASB16-AS1 regulates IGF1R and CDK6 mRNA expression through RNA-binding protein HuR. We then found that inhibition of ASB16-AS1 attenuates the binding of ubiquitin E3 ligase BTRC to HuR and subsequently inhibits HuR protein unbiquitination and degradation. BTRC knock-down could reverse the effect of AB16-AS1 on HuR, CDK6, and IGF1R levels. Collectively, these results demonstrate that ASB16-AS1 regulates adrenocortical carcinoma cell proliferation and tackling the level of ASB16-AS1 may be developed to treat adrenocortical carcinoma.

show abstract

<p>LncRNA ASB16-AS1 Promotes Growth And Invasion Of Hepatocellular Carcinoma Through Regulating miR-1827/FZD4 Axis And Activating Wnt/β-Catenin Pathway</p>

Cited by 24 publications

References 27 publications

<p>Long Non-Coding RNA ASB16-AS1 Functions as a miR-760 Sponge to Facilitate the Malignant Phenotype of Osteosarcoma by Increasing HDGF Expression</p>

<p>Long Non-Coding RNA ASB16-AS1 Functions as a miR-760 Sponge to Facilitate the Malignant Phenotype of Osteosarcoma by Increasing HDGF Expression</p>

Role of long noncoding RNA-mediated competing endogenous RNA regulatory network in hepatocellular carcinoma

Long noncoding RNA ASB16-AS1 inhibits adrenocortical carcinoma cell growth by promoting ubiquitination of RNA-binding protein HuR

Contact Info

Product

Resources

About